REFERENCES
1. Marks RM, Masch WR, Chernyak V. LI-RADS: past, present, and future, from the AJR special series on radiology reporting and data systems. AJR Am J Roentgenol 2021;216:295-304.
2. Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging diagnosis of hepatocellular carcinoma: the liver imaging reporting and data system, why and how? Clin Liver Dis 2020;24:623-36.
3. Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging 2019;50:746-55.
4. Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289:816-30.
5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
6. Hong CW, Park CC, Mamidipalli A, et al. Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations. Eur Radiol 2019;29:5073-81.
7. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-55.
8. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-8.
9. Kierans AS, Song C, Gavlin A, et al. Diagnostic performance of LI-RADS version 2018, LI-RADS version 2017, and OPTN criteria for hepatocellular carcinoma. AJR Am J Roentgenol 2020;215:1085-92.
10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49-69.
11. Elsayes KM, Kielar AZ, Agrons MM, et al. Liver Imaging Reporting and Data System: an expert consensus statement. J Hepatocell Carcinoma 2017;4:29-39.
12. Russo MW, Wald C. Radiological diagnosis of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:190-3.
13. The American College of Radiology LI-RADS v2017 Core. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/Ultrasound-LI-RADS-v2017 [Last accessed on 10 Dec 2021].
14. Kielar AZ, Chernyak V, Bashir MR, et al. LI-RADS 2017: an update. J Magn Reson Imaging 2018;47:1459-74.
15. The American College of Radiology LI-RADS v2018 Core. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en [Last accessed on 10 Dec 2021].
16. Elmohr M, Elsayes KM, Chernyak V. LI-RADS: review and updates. Clin Liver Dis (Hoboken) 2021;17:108-12.
17. Kanmaniraja D, Chernyak V. Liver imaging reporting and data system and CT/MRI diagnosis of hepatocellular carcinoma. Hepatoma Res 2020;6:51.
18. Liu P, Xie SH, Hu S, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget 2017;8:68131-7.
19. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015;24:1-17.
20. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res 2007;37:239-47.
21. McGlynn KA, Sahasrabuddhe VV, Campbell PT, et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer 2015;112:1266-72.
22. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007;41:761-72.
23. Shropshire E, Mamidipalli A, Wolfson T, et al. LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study. Abdom Radiol (NY) 2020;45:3092-102.
24. Cannella R, Vernuccio F, Celsa C, et al. Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. Liver Int 2021;41:2179-88.
